Song Ruilin, executive chairman of China pharmaceutical promotion association, attended the 36th J.P. Morgan Health Industry Conference and delivered a speech at the Asia Forum

Source: Song Ruilin, executive chairman of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association"), attended the 36th J.P Morgan health industry conference held in San Francisco, U.S on January 10, 2018, and was invited to deliver a speech entitled "2017 major changes in China's drug regulation" at the luncheon held at the Asia Forum J The J.P Morgan Healthcare Conference has been held for 36 years It is a top-level event in the global medical industry and investment community, attracting many business leaders, investors and institutions from all over the world to discuss the future development trend of the industry and lead the development and investment direction of the global medical health field The Asia Forum held a luncheon for China at this session, which is the first time to introduce China's drug regulatory reform Song Ruilin, executive chairman, pointed out that the 19th National Congress of the Communist Party of China was held in 2017, announcing a new era in which China's economic development has changed from high-speed growth to high-quality growth In this context, 2017 is also a key year for the reform of China's pharmaceutical regulatory system In July 2017, China food and Drug Administration officially joined the International Council for coordination of technical requirements for human drugs (ICH), marking that China's drug review and approval standards and guiding principles will be fully integrated with the world, which is not only an important step in the internationalization of China's pharmaceutical industry, but also a common challenge for the whole industry In October 2017, the general office of the CPC Central Committee and the general office of the State Council jointly issued the opinions on deepening the reform of the review and approval system and promoting the innovation of pharmaceutical and medical devices, which opened a landmark comprehensive change in the history of Chinese pharmaceutical development President song gave a brief introduction to the reform document, pointing out that major reforms such as clinical trial management, patent link system, medical insurance access for innovative drugs, and listing license system will have a huge impact on the industry at home and abroad, and become a major good for the development of China's pharmaceutical market In addition, with the participation and promotion of China pharmaceutical promotion association, the Hong Kong Stock Exchange has allowed biotechnology enterprises with a market value of HK $1.5 billion and zero profit to apply for listing, which will effectively promote the docking of China's pharmaceutical innovation industry with the domestic and foreign capital circles He pointed out that driven by the above three major positive factors, China's pharmaceutical innovation industry will also usher in an investment boom and many opportunities President song also introduced the China Pharmaceutical Innovation and investment conference held by China pharmaceutical promotion association Since 2016, the success of the two sessions of China Pharmaceutical Innovation and investment conference has received warm response in the domestic industry The third session of China Pharmaceutical Innovation and investment conference will be held in Suzhou on September 18, 2018, and the number of participants is expected to exceed 3000 People from domestic and foreign pharmaceutical circles are welcome to pay attention to and attend the conference to share the achievements of China pharmaceutical industry reform and development President Song Ruilin delivered a speech at the JPMorgan health industry conference President Song Ruilin answered questions after the report